Preview

ПОРАЖЕНИЕ МИОКАРДА ПРИ ТИРЕОТОКСИКОЗЕ: ОСОБЕННОСТИ ТЕЧЕНИЯ, ИСХОДЫ, ОТДАЛЕННЫЙ ПРОГНОЗ

https://doi.org/10.14341/ket20062421-30

Полный текст:

Об авторах

V Y Shulgina



V Fadeyev

Кафедра эндокринологии


G Melnichenko

Кафедра эндокринологии


Список литературы

1. Акимова Ю.К., Казакова Г.Н. // Кардиология. 1985. № 7. С. 121-122.

2. Гольбер Л.М., Кандрор В.И. Тиреотоксическое сердце. М., 1972.

3. Горобец В.Ф., Коробченко З.А., Матвиенко Е.Г., Бирюков А. П. // Тер. архив. 1986. № 10. С. 100-104.

4. Левина Л.Н. Сердце при эндокринных заболеваниях. Л., 1989.

5. Фатенков В.Н., Семенов В.А. Состояние сердечно-сосудистой системы у больных тиреотоксикозом в ближайшие и отдаленные сроки после терапевтического и хирургического лечения. Куйбышев, 1974.

6. Adelmann G., Jahrbucher. // Philosoph. Med. Ges. Wurzburg. 1928. V. 1. P. 104-106.

7. Aghini-Lombardi F., Antonangeli L., Martino E. et al. The spectrum of thyroid disease in an iodine-deficient community: the Pescopagano survey // J. Clin. Endocrinol. Metab. 1999. V. 84. P. 561-566.

8. Banovac K., Papic M., Bilsker M.S. et al. Evidence of hyperthyroidism in apparently euthyroid patients treated with levo-thyroxine // Arch. Intern. Med. 1989. V. 149. P. 809-812.

9. Bauerlein E.J., Chakko C.S., Kessler K.M. Reversible dilated cardiomyopathy due to thyrotoxicosis // Am. J. Cardiol. 1992. V. 70. P. 132-138.

10. Bell G.M., Sawers J.S., Forfar J.C. et al. The effect of minor increments in plasma thyroxine on heart rate and urinary sodium excretion // Clin. Endocrinol. 1983. V. 18. P. 511-516.

11. Benjamin E.J., Wolf P.A., D’Agostino R.B. et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study // Circulation. 1988. V. 98. P. 946-952.

12. Biondi B., Fazio S., Carella C. et al. Cardiac effect of long term thyrotropin-supressive therapy with levothyroxine // J. Clin. Endocrinol. Metab. 1993. V. 77. P. 33-38.

13. Biondi B., Fazio S., Cuocolo A. et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine // J. Clin. Endocrinol. Metab. 1996. V. 81. P. 4224-4228.

14. Biondi B., Fazio S., Palmieri E. A. et al. Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiacmorphology and function // Cardiologia. 1999. V. 44. P. 443-449.

15. Biondi B., Palmieri E.A., Fazio S. et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients // J. Clin. Endocrinol. Metab. 2000. V. 85. P. 4701-4705.

16. Boutin J.M., Matte R., D’Amour P. et al. Characteristics of patients with normal T3 and T4 and a low TSH response to TRH // Clin. Endocrinol. 1986. V. 25. P. 579-588.

17. Canaris G.J., Manowitz N.R., Mayor G. et al. The Colorado thyroid disease prevalence study // Arch. Intern. Med. 2000. V. 160. P. 526-534.

18. Cavallo A., Joseph C.J., Casta A Cardiac complications in juvenile hyperthyroidism // Amer. J. Dis. Child. 1984. V. 138. P. 479-482.

19. Ching G.W., Franklyn J.A., Stallard T.J. et al. Cardiac hypertrophy as a result of long-term thyroxine therapy and thyrotoxicosis // Heart. 1996. V. 75. P. 363-368.

20. Dillmann W.H. The Thyroid. 6-th Ed. / Eds L.E. Braverman, R.D. Otiger. Philadelphia, 1991.

21. Fazio S., Biondi B., Carella C. et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levo-thyroxine: beneficial effect of beta-blockade // J. Clin. Endocrinol. Metab. 1995. V. 80. P. 2222-2226.

22. Fatourechi V., Edwards W. D. Graves’ disease and low-output cardiac dysfunction: implications for autoimmune disease in endomyocardial biopsy tissue from eleven patients // The Lancet. 2000. V. 10 (7). P. 601-601.

23. Forfar J.C., Miller H., Toft A.D. Occult thyrotoxicosis: a reversible cause of “idiopathic” atrial fibrillation // Am. J. Cardiol. 1979. V. 44. P. 9-15.

24. Forfar J.C., Muir A.L., Sawers S.A. et al. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy // N. Engl. J. Med. 1982. V. 307. P. 1165-1175.

25. Franklyn J., Maisonneuve P., Sheppard M. et al. Mortality after treatment of hyperthyroidism with radioactive iodine // N. Engl. J. Med. 1998. V. 338. P. 712-718.

26. Frost L., Vestergaard P., Mosekilde L. Hyperthyroidism and risk factors of atrial fibrillation or flutter: a population-based study // Arch. Intern. Med. 2004. V. 164. P. 1675-1678.

27. Furberg C.D., Psaty B.M., Manolio T.A. et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) // Am. J. Cardiol. 1994. V. 74. Р. 236-241.

28. Gilligan D. M., Ellenbogen K. A., Epstein A. E. The management of atrial fibrillation // Am. J. Med. 1996. V. 101. P. 413-421.

29. Graves R.A. // London. Med. A Surg. J. (Renshaw’s). 1835. V. 7. P. 516-522.

30. Grund F.M., Niewoehner C.B. Hyperthyroxinemia in patients receiving thyroid replacement therapy // Arch. Intern. Med. 1989. V. 149. P. 921-924.

31. Haissaguerre M., Jais P., Shah D. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating from in the pulmonary veins // N. Engl. J. Med. 1998. V. 339. P. 659-666.

32. Hall P., Lundell G., Holm L.E. Mortality in patient treated with hyperthyroidism with iodine-131 // Acta Endocrinol. 1993. V. 128. P. 230-234.

33. Hollowell J.G., Staehling N.W., Hannon W.H. et al. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III) // J. Clin. Endocrinol. Metab. 2002. V. 87. P. 488-499.

34. Hrnciar J. Cor thyreotoxicum. Part I - new findings about its etiopathogenesis and diagnosis. Overview of the problem based on 35 years’ experience // Vntr. Lek. 2002. V. 48(1). P. 38-43.

35. Jennings P.E., O’Malley B.P., Griffin K.E. et al. Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: a case for “tissue thyrotoxicosis” // Br. Med. J. 1984. V. 289. P. 1645-1647.

36. Kahaly G., Mohr-Kahaly S., Hellermann J. Heart and Thyroid. Wien, 1994.

37. Kahaly G. Graves’ disease and mitral valve prolapse // JAMA. 1987. V. 257. P. 22-28.

38. Kiss E., Jakab G., Kranias E. G. et al. Thyroid hormone-induced alterations in phospholamban protein expression: regulatory effects on sarcoplasmic reticulum Ca2+ transport and myocardial relaxation // Circ. Res. 1994. V. 75. P. 245-251.

39. Klein I., Ojamaa K. Thyroid hormone and cardiovascular system // N. Engl. J. Med. 2001. V. 344. P. 501-509.

40. Klein I., Ojamaa K. The cardiovascular system in hypothyroidism. In: Braverman L. E., Utiger R. D., eds. Werner & Ingbar’s the thyroid: a fundamental and clinical text. 8th ed. Philadelphia: Lippincott Williams & Wilkins, 2000.

41. Klein I., Ojamaa K. Thyrotoxicosis and the heart // Endocrinol. Metab. Clin. North. Am. 1998. V. 27. P. 51-62.

42. Klien I. Thyroid hormone and the cardiovascular system // A.M.J. Med. 1990. V. 88. P. 631-637.

43. Krahn A.D., Klein G.J., Kerr C.R. et al. How useful is thyroid function testing in patients with recent-onset atrial fibrillation? // Arch. Intern. Med. 1996. V. 156. P. 2221-2230.

44. Kraus R. // Wien. Klin. Wschr. 1889. V. 12. P. 416-423.

45. Ladefnson P.W. Thyrotoxicosis and the heart: something old and something new [Editorial] // J. Clin. Endocrinol. Metab. 1993. V. 77. P. 332-333.

46. Laurberg P., Nohr S.B., Pedersen K. M. et al. Thyroid disorders in mild iodine deficiency // Thyroid. 2000. V. 11. P. 951-963.

47. Lauberg P., Pederson K.M., Vestergaard H. et al. High incidence of multinodular toxic goiter in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative survey of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland // J. Intern. Med. 1991. V. 229. P. 415-423.

48. Levey G.S., Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism // Am. J. Med. 1990. V. 88. P. 642-646.

49. Liggett S.B., Shah S.D., Cryer P.E. Increased fat and skeletal muscle b-adrenergic receptors but unaltered metabolic and hemodynamic sensitivity to epinephrine in vivo in experimental human thyrotoxicosis // J. Clin. Invest. 1989. V. 83. P. 803-809.

50. Lombardi G., Biondi B., Fazio S. et al. Heart and Thyroid. Wien, 1994.

51. Lutton S., Ratliff N., Yuong J. Cardiomyopathy and myocardial failure. 2001.

52. Marks A.D., Channick B.J., Adlin E. V. et al. Chronic thyroiditis and mitral valve prolapse // Ann. Intern. Med. 1985. V. 102. P. 479-483.

53. Marqusee E., Haden S. T., Utiger R.D. Subclinical thyrotoxicosis // Endocrinol. and Metab. Clin. of N. Am. 1998. V. 27. P. 37-49.

54. Marti V., Ballester M., Rigla M. Myocardial damage does not occurred in untreated hyperthyroidism unless associated with congestive heart failure // Am. Heart J. 1997. V. 134. P. 1134-1137.

55. Martin W.H., Spina R.J., Korte E. Effect of hyperthyroidism of short duration on cardiac sensitivity to b-adrenergic stimulation // J. Am. Coll. Cardiol. 1992. V. 19. P. 1185-1194.

56. Mercuro G., Panzuto M.G., Bina A. et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levo-thyroxine: effect of individual dose tailoring // J. Clin. Endocrinol. Metab. 2000. V. 85. P. 159-164.

57. Mintz G., Pizzarello R., Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment // J. Clin. Endocrinol. Metab. 1991. V. 73. P. 146-150.

58. Moebius P.J. Die Basedowische Krankheit. Ed. H. Holder. Wien, 1906.

59. Nakazawa H.K., Sakurai K., Hamada N. et al. Management of atrial fibrillation in the post-thyrotoxic state // Am. J. Med. 1982. V. 72. P. 903-909.

60. Nordyke R.A., Gilbert F. Jr., Harada A. Graves’ disease: influence of age on clinical findings // Arch. Intern. Med. 1988. V. 148. P. 626-631.

61. Osman F., Daykin J., Sheppard M., Franklyn J. et al. Cardiac rhythm abnormalities in thyrotoxicosis: The explanation for exess of vascular mortality // J. Endocrinol. 2000. V. 164. P. 321-326.

62. Osman F., Gammage M., Franklyn J. Hyperthyroidism and Cardiovascular Morbidity and Mortality // Thyroid. 2002. V. 12. P. 483-487.

63. Parle J., Maisonneuve P., Sheppard M., Boyle P., Franklyn J. A single low thyrotropin (TSH) concentration predicts increased allcause and cardiovascular mortality in older persons in the community: a 10 year cohort study // Lancet. 2001. V. 358. P. 861-870.

64. Petersen P., Hansen J. Stroke in thyrotoxicosis with atrial fibrillation // Stroke. 1988. V. 19. P. 15-21.

65. Polikar R., Burger A. G., Scherrer U. et al. The thyroid and the heart // Circulation. 1993. V. 87. P. 1435- 1441.

66. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies // Circulation. 1996. V. 93. P. 841-842.

67. Roffi M., Cattaneo F., Topol E.J. Thyrotoxicosis and the cardiovascular system: Subtle but serious effects. // Cleveland Clin. J. оf Med. 2003. V. 70. P. 57- 63.

68. Sachs R.N., Valensi P. Reversible cardiomyopathy due to thyrotoxicosis // Am. J. Cardiol. 1993. V. 71. P. 501-508.

69. Samuels M.H. Subclinical thyroid disease in the elderly // Thyroid. 1998. V. 8. P. 803- 813.

70. Sandler G., Wilson G.M. The nature and prognosis of heart disease in thyrotoxicosis: a review of 150 patients treated with 131I // QJM. 1959. V. 28. P. 347-352.

71. Sawin C.T., Castelli W.P., Hershman J.M. et al. The aging thyroid. Thyroid deficiency in the Framingham Study // Arch. Intern. Med. 1985. V. 145. P. 1386-1388.

72. Sawin C.T., Geller A., Wolf P.A. et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons // N. Eng.l J. Med. 1994. V. 331. P. 1249-1254.

73. Sgarbi J.A., Villaca F., Scandiuzzi S. et al. Improvement of cardiac effects of endogenous subclinical hyperthyroidism with methimazol treatment [Abstract]. 12th International Thyroid Congress. Kyoto. - 2000 // Endocr. J. 2000. V. 47(Suppl). P. 179-182.

74. Shapiro L.E. , Sievert R., Ong L. et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine // J. Clin. Endocrinol. Metab. 1997. V. 82. P. 2592-2595.

75. Shimizu T., Koide S., Yoshimura Noh J. et al. Hyperthyroidism and the management of atrial fibrillation // Thyroid. 2002. V. 12. P. 811-823.

76. Sun Z.Q., Ojamaa K., Coetzee W.A. et al. Effects of thyroid hormone on action potential and repolarizing currents in rat ventricular myocytes // Am. J. Physiol. Endocrinol. Metab. 2000. V. 278. P. 302-307.

77. Sun Z.Q., Ojamaa K., Nakamura T.Y. et al. Thyroid hormone increases pacemaker activity in rat neonatal cardiac myocytes // J. Mol. Cell. Cardiol. 2001. V. 33. P. 811- 815.

78. Tenerz A., Forberg R., Jansson R. Is a more active attitude warranted in patients with subclinical thyrotoxicosis? // J. Intern. Med. 1990. V. 228. P. 229-233.

79. Tunbridge W., Evered D., Hall R. The spectrum of thyroid disease in the community: the Wickham survey // Clin. Endocr. 1977. V. 7. P. 481-489.

80. Tseng K.H., Walfish P.G., Persaud J.A. et al. Concurrent aortic and mitral valve echocardiography permits measurement of systolic time intervals as an index of peripheral tissue thyroid functional status // J. Clin. Endocrinol. Metab. 1989. V. 69. P. 633-638.

81. Vanderpump M.P., Tunbridge W.M., French J.M. et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community // Thyroid. 1996. V. 6. P. 155-160.

82. Wang C., Crapo L.M. The epidemiology of thyroid diseases and implications for screening // Endocrinol. and Metab. Clin. of N. Am. 1977. V. 26. P. 189-218.

83. Weetman A.P. Grave’s Disease // N. Engl. J. Med. 2000. V. 343. P. 1236-1248.

84. Woeber K.A. Thyrotoxicosis and the heart // N. Engl. J. Med. 1992. V. 327. P. 94-97.

85. Wolf P.A., Benjamin E.J., Belanger A.J. et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study // Am. Heart J. 1996. V. 131. P. 790-795.


Для цитирования:


Shulgina V.Y., Fadeyev V., Melnichenko G. ПОРАЖЕНИЕ МИОКАРДА ПРИ ТИРЕОТОКСИКОЗЕ: ОСОБЕННОСТИ ТЕЧЕНИЯ, ИСХОДЫ, ОТДАЛЕННЫЙ ПРОГНОЗ. Клиническая и экспериментальная тиреоидология. 2006;2(4):21-30. https://doi.org/10.14341/ket20062421-30

For citation:


., ., . Myocardial lesion in hyperthyroidism: natural history, outcomes, prognosis. Clinical and experimental thyroidology. 2006;2(4):21-30. (In Russ.) https://doi.org/10.14341/ket20062421-30

Просмотров: 20


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)